Cargando…
P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
Autores principales: | Shah, Bijal, Xue, Mei, Yang, Keri, Liu, Sizhu (Tom), Tang, Boxiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431129/ http://dx.doi.org/10.1097/01.HS9.0000971336.22348.b6 |
Ejemplares similares
-
Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
por: Liu, Shuozi, et al.
Publicado: (2022) -
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023) -
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
por: Rule, Simon A., et al.
Publicado: (2019) -
P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022) -
Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2022)